ClinicalTrials.gg
RecruitingNCT06939387Updated Apr 22, 2025

Drug-induced Kidney Injury Model

An observational study in Acute Kidney Injury, sponsored by Zhejiang Provincial People's Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Zhejiang Provincial People's Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Planned enrollment
31st of 105
1,500 · median 472
Started
2025
with 9 others
Observational
105 of 168
26 open now
Primary completion
2026-12
later than 21 of 53 live
Registered
128th of 168
by date

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 31st largest by planned enrollment of the 105 observational ones that give a count, is one of 10 that started in 2025, is one of 105 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 128th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

To establish the prediction model of renal dysfunction in patients with drug-induced renal injury and study the prognosis of different drug treatments

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • acute kidney injury
  • drug
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Drug-induced acute kidney injury

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Drug-induce acute kidney injury

Exclusion criteria

Exclusion Criteria:

  • 1.Dialysis patients; 2.No baseline creatinine; 3.Obstructive AKI; 4.Clinical data were incomplete.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Drug induced acute kidney injury

    Patients with acute kidney injury caused by the use of nephrotoxic drugs

    Other: Observational study, no intervention

Interventions

  • OtherObservational study, no intervention

    Observational study, no intervention

06

What researchers measure

Primary outcomes

  1. Model performance metrics assessed by AUC-ROC, accuracy and F1-score using 10-fold cross-validation

    The prognosis of renal function was evaluated by measuring creatinine and proteinuria by laboratory tests. Predict outcomes using machine learning methods. And the prediction effect of the prediction model was evaluated by AUC-ROC, F1, accuracy and other indicators.

    Time frame: through study completion, an average of 6 months

Secondary outcomes

  1. The rate at which creatinine falls

    Time frame: 7 days, 1 month, 3 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — We will publish relevant research papers, patient data is not appropriate for public disclosure

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 21 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Apr 22, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939387
Lead sponsor
Zhejiang Provincial People's Hospital
Collaborators
Taizhou Enze Hospital, Hangzhou Linping District first People's Hospital, Aksu district first People's Hospital, Ningbo Yinzhou District Second Hospital, Wucheng District First People's Hospital
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Mar 10, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 22, 2025

Study contacts

xiaolan Ye, master
Contact
yexl1120@126.com
+86-0571-85893117
Ping Huang, doctor
Contact
huangping1841@zjcc.org.cn
+86-0571-85893117

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion